A misused Facebook post can help companies gather evidence against former employees who steal trade secrets (“How To Gather Digital Evidence of Trade Secret Theft”) and can reverse a litigant’s chances in court (“Facebook Posts Can Backfire in Court”). But now a Facebook page is coming under scrutiny for a pharmaceutical failure to warn.

In Epstein Becker Green’s Toxic Tort Litigation blog, William Ruskin explains that drugmaker IBSA Institut Biochimique S.A. posted on its Facebook page about using the drug Tirosint to combat hypothyroidism. However, the Food and Drug Administration didn’t approve this diagnosis and warned the company “that its Facebook webpage was false or misleading because it made representations about the efficacy of Tirosint, but failed to communicate any risk information associated with its use and omitted material facts,” Ruskin said.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]